April 23, 2024

Medical Trend

Medical News and Medical Resources

Cuba Lung Cancer Vaccine CIMAvax-EGF: Pioneering Hope for Long-Term Survival

Cuba Lung Cancer Vaccine CIMAvax-EGF: Pioneering Hope for Long-Term Survival



Cuba Lung Cancer Vaccine CIMAvax-EGF: Pioneering Hope for Long-Term Survival

50% of late-stage lung cancer patients survive over 3 years! Cuban lung cancer vaccine emerges, rekindling hope for life!

Against the backdrop of rapidly advancing global medical technology, a research achievement from the Caribbean gem, Cuba, is quietly ushering in a new chapter in the battle against cancer. This is the Cuban lung cancer vaccine, CIMAvax-EGF, hailed as the “first of its kind globally” and attracting global attention. This vaccine’s uniqueness lies in its targeting not viruses but malignant tumors, especially non-small cell lung cancer.

CIMAvax-EGF is a potential vaccine for treating late-stage NSCLC with minimal side effects. It was approved in Cuba in 2008 for use as a therapeutic anti-cancer vaccine in adult patients with stage III B/IV NSCLC. Unlike preventive vaccines, patients treated with the Cuban lung cancer vaccine have a two-fold increase in survival compared to those not treated with the vaccine.

More than 5,000 lung cancer patients have received CIMAvax-EGF treatment. Multiple international studies have shown that patients treated with CIMAvax-EGF experience prolonged tumor stabilization time, overall survival, and improved quality of life. CIMAvax-EGF has been approved for lung cancer treatment in Argentina, Bosnia and Herzegovina, Colombia, and Cuba.

50% of late-stage lung cancer patients survive over 3 years! Latest phase II data of the Cuban lung cancer vaccine revealed!

CIMAvax-EGF (CE) is a recombinant anti-human epidermal growth factor (EGF) immunotherapy. It has previously shown to improve survival in late-stage NSCLC patients as a maintenance therapy after platinum-based chemotherapy.

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, medical researchers presented the latest results of a phase II trial of CIMAvax-EGF combined with Nivolumab (N) as second-line (2L) therapy for late-stage non-small cell lung cancer patients after platinum-based chemotherapy, showing remarkable efficacy!

The study included 23 patients with non-small cell lung cancer who had previously received immunotherapy and were treated with CIMAvax-EGF combined with Nivolumab as maintenance therapy after platinum-based chemotherapy every 2 weeks.

Cuba Lung Cancer Vaccine CIMAvax-EGF: Pioneering Hope for Long-Term Survival

The results showed that in 21 evaluable patients [17 with non-squamous histology, 12 with KRAS wild-type, 13 with PD-L1 tumor proportion score (TPS) of 0, and 7 with KRAS mutations], the disease control rate was 47.6% (n=10), the 3-year overall survival rate was 29%, and the median overall survival was 11.9 months. Compared to patients with non-squamous histology, those with squamous histology had a higher 3-year overall survival rate of up to 50%, indicating that half of the advanced lung squamous cell carcinoma patients survived for 3 years.

Patients with PD-L1 expression ≥1% had a higher 3-year overall survival rate of up to 38% and a 3-year progression-free survival rate of 38%, while those without PD-L1 expression had a 3-year overall survival rate of 23% and a 3-year progression-free survival rate of 8%.

The median overall survival was 31.7 months, the 1-year overall survival rate was 67%, and the 3-year overall survival rate was 50% for EGFR/ALK/KRAS wild-type patients, while for KRAS-mutant non-small cell lung cancer patients, the median overall survival was 10.1 months, the 1-year overall survival rate was 29%, and the 3-year overall survival rate was 0.

The results suggest that NSCLC patients who receive CIMAvax-EGF combined with Nivolumab have a better overall survival than historical cohorts treated with single-agent Nivolumab as second-line therapy! This offers new hope for patients seeking long-term survival and freedom from recurrence!

Nearly half of the patients survive for ≥2 years, Cuban lung cancer vaccine opens the way for long-term survival.

In April 2023, a real-world study on Cimavax-EGF lung cancer vaccine as maintenance therapy for advanced non-small cell lung cancer patients was published in J Cancer, and its results were stunning!

The study included 106 patients aged 18 and older with stage IIIB and IV non-small cell lung cancer who were treated with the lung cancer vaccine CIMAvax-EGF after showing objective response or disease stabilization to first-line treatment (including platinum doublet, chemotherapy and radiotherapy, or single-agent chemotherapy). Patients with brain metastases or disease progression at the end of first-line treatment were excluded.

The results showed that the median overall survival after starting chemotherapy or radiotherapy was 22.46 months (almost 2 years), with survival rates of 97.7%, 82.7%, and 45.5% at 6, 12, and 24 months, respectively. This means that almost half of the patients survived for 2 years or longer.

An analysis of overall survival by age showed a median overall survival of 16.7 months for patients under 65 years old and 12.2 months for patients 65 years and older, indicating that patients under 65 with non-small cell lung cancer benefit more.

Regarding physical status, patients with ECOG 0 had a median overall survival of 29 months, while those diagnosed with ECOG-1 had a median overall survival of 11 months, indicating that patients with better physical status have a longer survival, almost doubling it!

Furthermore, CimaVax is not the only breakthrough in lung cancer treatment in Cuba. In 2013, a second-generation vaccine called Vaxira was approved in Cuba. This new drug can specifically target the NeuGcGM3 receptor on lung cancer cells and stimulate the body’s immune system, effectively treating non-small cell lung cancer.

The future looks promising! Cell immunotherapy is the ultimate weapon against cancer!

In addition to using the Cuban lung cancer vaccine as active immunotherapy to prevent recurrence, another way to prevent recurrence is through Adoptive Cell Transfer Therapy (ACT), a passive immunotherapy method. It involves isolating immune-active cells from cancer patients, expanding and functionally identifying them in vitro, and then reinfusing them into patients to directly kill tumor cells or stimulate the body’s immune response to kill tumor cells.

In fact, there are many types of cell immunotherapies for preventing recurrence, such as NK cell therapy, dendritic cell vaccine, CTL therapy, and composite immune cell therapy.\

 


Related news about Cuba Lung Cancer Vaccine

According to a report by Cuba’s Granma newspaper on February 9, 2013, the Cuban Center for Molecular Immunology has developed and registered a new vaccine for the treatment of lung cancer, RACOTUMOMAB.

This is the second lung cancer vaccine developed by the center after CIMAvaxEGF. The center’s largest scientific research achievement in 2012.

Agustín Lage, director of the Cuban Molecular Immunology Center, said that the new vaccine RACOTUMOMAB is easy to use, showed “exciting” effects in clinical trials, and was widely recognized at the European Society of Medical Oncology Congress, and its research paper was subsequently published in In The Lancet Oncology.

Lage said that RACOTUMOMAB will start mass production this year, which will allow more Cuban lung cancer patients to receive timely intervention and treatment. Its overseas registration is also on the schedule.

The development of RACOTUMOMAB enables Cuba to continue to maintain its leading position in the treatment of lung cancer worldwide. Cuba is the only country in the world that has researched and developed two lung cancer vaccines.

CIMAvaxEGF lung cancer vaccine is the only registered medicine of its kind in the world.

Cuba Lung Cancer Vaccine CIMAvax-EGF: Pioneering Hope for Long-Term Survival

(source:internet, reference only)


Disclaimer of medicaltrend.org


Important Note: The information provided is for informational purposes only and should not be considered as medical advice.